With REIMAGINE-4, we are comparing a potential new weight loss treatment called CagriSema to Tirzepatide (also known as Mounjaro®) in people with Type 2 Diabetes
This is a randomised, open label research project where participants will receive either CagriSema or Mounjaro® tirzepatide. The study aims to determine if CagriSema offers improved glucose and weight control for people living with Type 2 diabetes.

Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.